Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC
项目2:PDAC新抗原疫苗耐药机制
基本信息
- 批准号:10708575
- 负责人:
- 金额:$ 33.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-28 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvant ChemotherapyAgonistAlgorithmsBiologyBiomedical ResearchCD8B1 geneClinical TrialsClinical Trials DesignCorrelative StudyCoupledDNA VaccinesDataDevelopmentDimensionsEnrollmentFLT3 ligandFunctional disorderFundingGenerationsHumanImmune responseImpairmentLicensingMalignant NeoplasmsMalignant neoplasm of pancreasNeoadjuvant TherapyOperative Surgical ProceduresPathway interactionsPatientsPeptide VaccinesPhase I Clinical TrialsPre-Clinical ModelPublishingResistanceRoleSignal TransductionSoftware ToolsSpecimenSynthetic AntigensT cell receptor repertoire sequencingT cell responseT-LymphocyteTNFRSF5 geneTestingTherapeuticTumor ImmunityTumor TissueUniversitiesVaccinationVaccine DesignVaccine TherapyVaccinesWashingtonanti-PD1 antibodiesanti-tumor immune responseantigen-specific T cellscancer immunobiologycancer immunotherapyearly phase clinical trialexhaustionfunctional improvementfunctional statusimprovedin vivoinnovationmanufactureneoantigen vaccineneoantigenspancreatic ductal adenocarcinoma modelpatient populationperipheral bloodpre-clinicalpredict clinical outcomeresistance mechanismresponserestraintsafety assessmentsingle-cell RNA sequencingsuccesstranslational studytrial designtumortumor microenvironmentvaccine platform
项目摘要
ABSTRACT
We have made important contributions to the immunobiology of cancer neoantigens, and have developed a
robust, publically available, and frequently downloaded suite of software tools for neoantigen prediction. With
support from our previous SPORE in Pancreatic Cancer and SU2C, we have now completed enrollment to two
phase 1 clinical trials in PDAC testing neoantigen DNA vaccines (NCT03122106) and synthetic long peptide
(SLP) vaccines (NCT03956056). Preliminary analyses confirm that both neoantigen vaccine platforms can
induce robust immune responses, and suggest that PDAC patients treated with neoantigen vaccines have
better than predicted clinical outcomes. We recently developed algorithms for the prioritization of class II
neoantigens and demonstrated that optimized vaccines incorporating both class I and II neoantigens improve
the success of neoantigen vaccines. With funding from Leidos Biomedical Research, we are currently testing
optimized neoantigen SLP vaccines in PDAC patients using a window trial design (NCT05111353).
Aim 1: Test the hypothesis that optimized neoantigen vaccines can increase the number and improve
the function of neoantigen-specific T cells in PDAC. We are currently testing optimized neoantigen
vaccines in PDAC patients following neoadjuvant chemotherapy in the window prior to surgery
(NCT05111353). The window clinical trial design provides the opportunity to study neoantigen-specific T cell
responses in the tumor microenvironment (TME) after vaccination. In Aim 1, we will use biospecimens from the
trial to rigorously assess the functional biology of neoantigen-specific T cells present in the TME using coupled
single-cell RNA sequencing (scRNA-seq) and TCR sequencing.
Aim 2: Test innovative strategies to address the paucity of cDC1 in PDAC. We have made important
contributions to understanding the development and biology of cDC1. We recently demonstrated that cDC1
orchestrate CD4 and CD8 immune responses in cancer, and that PDAC impairs development of cDC1,
restraining antitumor immunity. We are currently testing an innovative strategy to expand and license cDC1 in
PDAC (NCT04536077). We will test innovative strategies to enhance neoantigen vaccine therapy in PDAC by
expanding and licensing cDC1 in vivo. We will also test biospecimens from NCT05111353 and NCT04536077
to evaluate the impact of cDC1 paucity on the response to neoantigen vaccines.
Aim 3: Test the hypothesis that the TIGIT pathway restrains the response to optimized neoantigen
vaccines in PDAC. We and others have generated data using human specimens and preclinical models
suggesting that the TIGIT pathway restrains antitumor immune responses in PDAC. We propose correlative
studies to determine if TIGIT signaling also restrains neoantigen-specific T cell responses in human PDAC.
These studies have immediate translational relevance given that anti-TIGIT and anti-PD-1 antibodies are
currently being tested in early phase clinical trials
摘要
我们对癌症新抗原的免疫生物学做出了重要贡献,并开发了一种
用于新抗原预测的强大的、可在市场上获得的并且经常下载的软件工具套件。与
在我们之前胰腺癌和SU2C的SPORE的支持下,我们现在已经完成了两例入组
在PDAC中测试新抗原DNA疫苗(NCT 03122106)和合成长肽的I期临床试验
(SLP)疫苗(NCT 03956056)。初步分析证实,两种新抗原疫苗平台都可以
诱导强大的免疫应答,并表明用新抗原疫苗治疗的PDAC患者
优于预期的临床结果。我们最近开发了算法的优先级第二类
新抗原,并证明了优化的疫苗纳入I类和II类新抗原改善
新抗原疫苗的成功在Leidos生物医学研究的资助下,我们目前正在测试
使用窗口试验设计在PDAC患者中优化新抗原SLP疫苗(NCT 05111353)。
目的1:验证优化的新抗原疫苗可以增加数量并改善
新抗原特异性T细胞在PDAC中的功能。我们目前正在测试优化的新抗原
PDAC患者接受新辅助化疗后在手术前窗口期接种疫苗
(NCT 05111353)。窗口临床试验设计为研究新抗原特异性T细胞提供了机会
疫苗接种后肿瘤微环境(TME)的反应。在目标1中,我们将使用来自
使用偶联的免疫球蛋白抗体严格评估TME中存在的新抗原特异性T细胞的功能生物学的试验
单细胞RNA测序(scRNA-seq)和TCR测序。
目的2:测试创新策略以解决PDAC中cDC1的缺乏。我们已经取得了重要
对理解cDC1的发育和生物学的贡献。我们最近证明了cDC1
协调癌症中的CD4和CD8免疫应答,PDAC损害cDC 1的发育,
抑制抗肿瘤免疫。我们目前正在测试一项创新战略,以扩大和许可cDC 1,
PDAC(NCT 04536077)。我们将测试创新策略,以加强PDAC中的新抗原疫苗治疗,
在体内扩增和许可cDC1。我们还将检测来自NCT 05111353和NCT 04536077的生物标本
评价cDC1缺乏对新抗原疫苗应答的影响。
目的3:检验TIGIT途径抑制对优化的新抗原的应答的假设
PDAC疫苗我们和其他人已经使用人体标本和临床前模型生成了数据
表明TIGIT途径抑制PDAC中的抗肿瘤免疫应答。我们提出了相关的
本发明涉及用于确定TIGIT信号传导是否也抑制人PDAC中的新抗原特异性T细胞应答的研究。
考虑到抗TIGIT和抗PD-1抗体是
目前正在进行早期临床试验
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM G HAWKINS其他文献
WILLIAM G HAWKINS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM G HAWKINS', 18)}}的其他基金
Preclinical development of the novel inhibitor of apoptosis proteins S2/IAPinh for cancer therapy
用于癌症治疗的新型凋亡蛋白抑制剂 S2/IAPinh 的临床前开发
- 批准号:
10568409 - 财政年份:2022
- 资助金额:
$ 33.69万 - 项目类别:
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)
ACXT-3102 治疗胰腺癌 (PDAC) 的临床前开发
- 批准号:
10435565 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)
ACXT-3102 治疗胰腺癌 (PDAC) 的临床前开发
- 批准号:
10251498 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Washington University SPORE in Pancreatic Cancer
华盛顿大学 SPORE 在胰腺癌中的应用
- 批准号:
9982223 - 财政年份:2016
- 资助金额:
$ 33.69万 - 项目类别:
Washington University SPORE in Pancreatic Cancer
华盛顿大学 SPORE 在胰腺癌中的应用
- 批准号:
9146190 - 财政年份:2016
- 资助金额:
$ 33.69万 - 项目类别:
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER
SIGMA-2/拟肽结合物靶向胰腺癌中的细胞凋亡
- 批准号:
8630870 - 财政年份:2012
- 资助金额:
$ 33.69万 - 项目类别:
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER
SIGMA-2/拟肽结合物靶向胰腺癌中的细胞凋亡
- 批准号:
8219912 - 财政年份:2012
- 资助金额:
$ 33.69万 - 项目类别:
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER
SIGMA-2/拟肽结合物靶向胰腺癌中的细胞凋亡
- 批准号:
8463148 - 财政年份:2012
- 资助金额:
$ 33.69万 - 项目类别:
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER
SIGMA-2/拟肽结合物靶向胰腺癌中的细胞凋亡
- 批准号:
8879063 - 财政年份:2012
- 资助金额:
$ 33.69万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 33.69万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 33.69万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 33.69万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 33.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 33.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 33.69万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 33.69万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 33.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)